Lentiform Nucleus Hyperechogenicity in Parkinsonian Syndromes: A Systematic Review and Meta-Analysis with Consideration of Molecular Pathology.
Parkinson´s disease
hyperechogenicity
nucleus lentiformis
transcranial sonography
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
18 12 2019
18 12 2019
Historique:
received:
24
09
2019
revised:
03
12
2019
accepted:
14
12
2019
entrez:
22
12
2019
pubmed:
22
12
2019
medline:
19
8
2020
Statut:
epublish
Résumé
The hyperechogenicity of the substania nigra (SN) has been established as a valid finding in patients with Parkinson´s disease (PD), probably caused by an increased tissue iron concentration in the SN. The application of transcranial sonography (TCS) has been investigated for further echogenic basal ganglia alterations in patients with extrapyramidal movement disorders. Compared to PD, a hyperechogenic nucleus lentiformis (LN) has been reported to appear more frequently in atypical parkinsonian syndromes (aPS) such as the parkinsonian phenotype of multiple system atrophy (MSA-P) or the progressive supranuclear palsy (PSP). As the evidence providing study sizes are small, we conduct the first meta-analysis of the prevalence of LN hyperechogenicity in PD and aPS. We search for available studies providing prevalence of LN hyperechogenicity in patients with PD and aPS (MSA-P and PSP) detected by TCS in MEDLINE and SCOPUS databases. We calculate the prevalence rates of LN hyperechogenicity detection in patients with clinical diagnosis of PD vs. aPS under the random-effects model. We include a total of 1330 patients, 1091 PD and 239 aPS (MSA-P and PSP). We find a significantly higher prevalence of LN hyperechogenicity in aPS (76%, 95% CI: 0.62-0.88) compared to PD (16%, 95% CI: 0.10-0.23). After proving a higher prevalence of LN hyperechogenicity in aPS compared to PD, its histopathological cause needs to be investigated. Furthermore, its full diagnostic accuracy and the qualification to serve as a risk factor for MSA-P and PSP should also be questioned in future studies.
Identifiants
pubmed: 31861253
pii: cells9010002
doi: 10.3390/cells9010002
pmc: PMC7016776
pii:
doi:
Types de publication
Comparative Study
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Mov Disord. 2017 Jun;32(6):853-864
pubmed: 28467028
J Neural Transm (Vienna). 2002 Feb;109(2):191-6
pubmed: 12075859
Neurol Sci. 2017 Oct;38(10):1805-1810
pubmed: 28726052
J Neurochem. 1994 Sep;63(3):793-807
pubmed: 7519659
Neurol Sci. 2018 Nov;39(11):1887-1894
pubmed: 30088164
Mov Disord. 2015 Oct;30(12):1600-11
pubmed: 26474317
J Alzheimers Dis. 2018;61(4):1253-1273
pubmed: 29376857
Lancet Neurol. 2017 Jul;16(7):552-563
pubmed: 28653647
Front Neurol. 2019 Feb 12;10:74
pubmed: 30809185
Brain. 1994 Aug;117 ( Pt 4):835-45
pubmed: 7922469
FEBS Lett. 2002 Jan 16;510(3):216-20
pubmed: 11801257
Neurol Sci. 2016 Mar;37(3):373-6
pubmed: 26650802
Parkinsonism Relat Disord. 2017 Sep;42:1-11
pubmed: 28647434
BMC Neurol. 2014 Mar 22;14:54
pubmed: 24655437
Neurology. 1996 Jul;47(1):1-9
pubmed: 8710059
J Neurol Neurosurg Psychiatry. 2005 Mar;76(3):423-5
pubmed: 15716540
Parkinsonism Relat Disord. 2017 Mar;36:76-82
pubmed: 28108264
J Neurol. 2006 Apr;253(4):448-54
pubmed: 16267638
J Neurochem. 2001 Mar;76(6):1766-73
pubmed: 11259494
Brain. 1991 Aug;114 ( Pt 4):1953-75
pubmed: 1832073
Neurology. 2008 Aug 26;71(9):670-6
pubmed: 18725592
J Neural Transm (Vienna). 2006 Jun;113(6):775-80
pubmed: 16755382
Mov Disord. 2005 Oct;20(10):1278-85
pubmed: 15986424
Mov Disord. 2010 Apr 15;25(5):642-6
pubmed: 20175211
J Ultrasound Med. 2014 Dec;33(12):2069-74
pubmed: 25425362
Sci Rep. 2016 Feb 16;6:20863
pubmed: 26878893
J Neural Transm (Vienna). 2017 Jul;124(7):869-879
pubmed: 28451942
AJNR Am J Neuroradiol. 2018 Jun;39(6):1047-1051
pubmed: 29622555
Biochem Pharmacol. 2003 Aug 1;66(3):489-94
pubmed: 12907248
Arch Neurol. 2002 Jun;59(6):999-1005
pubmed: 12056937
Neurology. 2003 Jan 14;60(1):74-7
pubmed: 12525721
BMC Neurol. 2012 Mar 08;12:12
pubmed: 22400906
Lancet Neurol. 2008 May;7(5):417-24
pubmed: 18394965
Mov Disord. 2005 Mar;20(3):383-5
pubmed: 15486999
Med Arch. 2017 Aug;71(4):261-264
pubmed: 28974846
Mov Disord. 2015 Oct;30(12):1591-601
pubmed: 26474316
J Neural Transm (Vienna). 2014 Oct;121(10):1273-9
pubmed: 24615184
J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181-4
pubmed: 1564476
Ultrasound Med Biol. 2019 Mar;45(3):628-641
pubmed: 30612821
J Neural Transm (Vienna). 2015 Jun;122(6):863-5
pubmed: 25204278
J Clin Epidemiol. 2009 Oct;62(10):e1-34
pubmed: 19631507
Arch Neurol. 2007 Nov;64(11):1635-40
pubmed: 17998447
J Neurol. 2011 Apr;258(4):590-5
pubmed: 21042808
Lancet Neurol. 2014 Oct;13(10):1045-60
pubmed: 25231526
J Neurochem. 2001 Oct;79(2):225-36
pubmed: 11677250
Lancet Neurol. 2008 Nov;7(11):1044-55
pubmed: 18940694
Int Rev Neurobiol. 2010;90:237-57
pubmed: 20692506
Ultrasound Med Biol. 1999 Jul;25(6):901-4
pubmed: 10461717